Guardant Health (GH) 7th Annual Healthcare Symposium summary

Key themes and industry context

• The symposium focused on the challenges of an aging population, rising healthcare spending, and the need for improved access to innovation and vaccines globally.

• Multi-cancer early detection (MCED) was highlighted as a transformative area, with advances in technology shifting cancer from a fatal to a more chronic, manageable disease.

• The agenda included panels on multi-cancer screening, consumer empowerment, aging in place, and vaccine access.

Approaches to multi-cancer early detection

• Companies are pursuing different strategies: some develop broad multi-cancer tests from the outset, while others expand from single-cancer to multi-cancer detection.

• Partnerships between diagnostic firms, healthcare providers, and research institutions are central to expanding access and building evidence for new tests.

• Quest leverages its vast infrastructure and partnerships to provide access and choice, while also developing its own risk assessment tools.

Evidence, economics, and policy

• Early detection is modeled to reduce stage IV cancer incidence by over 40% and overall mortality by 18%, with significant cost savings compared to late-stage treatment.

• Demonstrating clinical utility and cost-effectiveness is crucial for payer and government adoption; legislative efforts are underway to secure Medicare coverage for MCED.

• Serial annual testing is recommended due to cancer's evolving nature, with combined tests offering greater economic value than multiple single-cancer screens.